← IonQ, Inc.
| Annual Trend | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Net loss | ($15.4m) | ($106.2m) | ($48.5m) | ($157.8m) | ($331.6m) | ($512.1m) | — | |
| Depreciation and amortization | $1.4m | $2.5m | $5.6m | $10.4m | $18.7m | $82.0m | $154.0m | |
| Amortization of premiums and accretion of discounts on available-for-sale securities | — | — | ($1.6m) | ($9.7m) | ($8.8m) | ($8.3m) | — | |
| Deferred income taxes | — | — | — | $0 | $0 | ($44.9m) | ($42.4m) | |
| Stock-based compensation | $1.2m | $7.7m | $31.5m | $69.7m | $106.9m | $312.0m | $450.0m | |
| Accounts receivable | ($290k) | ($317k) | ($1.5m) | ($8.2m) | $1.6m | ($37.7m) | ($62.6m) | |
| Accounts payable | $96k | $763k | $1.1m | $2.2m | ($601k) | ($7.6m) | $5.9m | |
| Property and equipment purchases in accounts payable and accrued expenses | $0 | $553k | $485k | $773k | $1.1m | $1.3m | — | |
| Intangible asset purchases in accounts payable and accrued expenses | $0 | $83k | $164k | $254k | $77k | — | — | |
| Accrued expenses and other current liabilities | $374k | $1.3m | $1.3m | $3.3m | ($411k) | $7.4m | — | |
| Unearned revenue | $1.4m | $3.6m | $3.9m | $2.6m | ($1.8m) | $9.3m | — | |
| Prepaid expenses and other current assets | ($699k) | ($3.8m) | ($7.0m) | ($14.4m) | ($15.2m) | ($72.2m) | — | |
| Other assets and liabilities | — | ($1.7m) | ($269k) | $1.9m | $3.2m | ($8.5m) | — | |
| Net cash provided by (used in) operating activities | ($12.0m) |
($26.5m)
-121.01%
|
($44.7m)
-68.44%
|
($78.8m)
-76.32%
|
($105.7m)
-34.10%
|
($283.2m)
-167.96%
|
($452.4m)
-59.74%
|
|
| Purchases of property and equipment | ($10.0m) | ($7.8m) | ($9.3m) | ($13.7m) | ($18.0m) | ($16.4m) | ($29.3m) | |
| Issuance of common stock for intellectual property | $0 | $1.6m | $0 | — | — | — | $3.0b | |
| Equity issued for acquisitions | — | — | — | $0 | $0 | $2.6b | — | |
| Other investing, net | — | — | — | ($5.8m) | ($5.6m) | ($4.2m) | — | |
| Net cash provided by (used in) investing activities | ($11.7m) | ($213.8m) | ($309.1m) | $68.8m | $82.7m | ($2.1b) | ($1.5b) | |
| Proceeds from Issuance of Common Stock | — | — | — | $0 | $0 | $3.3b | $3.0b | |
| Issuance of common stock for research and development arrangement | $2.9m | $814k | $0 | — | — | — | $3.0b | |
| Other financing, net | — | — | $37k | ($193k) | $238k | $7.9m | — | |
| Net cash provided by (used in) financing activities | $276k |
$603.2m
+218460.51%
|
$1.1m
-99.82%
|
$1.8m
+60.68%
|
$41.7m
+2267.23%
|
$3.4b
+7956.71%
|
$3.0b
-10.54%
|
|
| Cash, cash equivalents and restricted cash at the beginning of the period | — | $399.0m | $46.4m | $38.1m | $56.8m | $1.0b | — | |
| Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash | — | — | $0 | ($2k) | $25k | $581k | — | |
| Net change in cash, cash equivalents and restricted cash | ($23.4m) | $362.9m | ($352.7m) | ($8.3m) | $18.8m | $980.9m | — | |
| Additional Supplementary Disclosures | ||||||||
| Additional Supplementary Disclosures | ||||||||
| (Gain) loss on change in fair value of warrant liabilities | $0 | $63.3m | ($30.1m) | $19.2m | $117.1m | ($66.7m) | — | |
| Offering costs associated with warrants | $0 | $4.3m | $0 | $0 | $0 | $45.7m | — | |
| Other, net | $77k | $101k | ($1.1m) | $1.5m | $4.8m | $18.4m | — | |
| Purchases of available-for-sale securities | $0 | ($203.8m) | ($605.7m) | ($298.4m) | ($296.3m) | ($2.7b) | — | |
| Maturities of available-for-sale securities | — | $0 | $310.0m | $386.8m | $418.1m | $682.8m | — | |
| Purchases of privately-held securities | — | — | — | $0 | $0 | ($88.5m) | — | |
| Businesses acquired, net of cash paid and acquired | — | — | — | $0 | ($15.5m) | $523k | — | |
| Proceeds from stock options exercised | $276k | $5.5m | $1.1m | $2.0m | $8.0m | $26.7m | — | |
| Proceeds from warrants exercised | — | — | $17k | $37k | $33.4m | $11.4m | — | |
| Tax withholding receipts related to vested and released restricted stock units | — | $0 | $2.0m | — | — | — | — | |
| Tax withholding payments related to vested and released restricted stock units | — | $0 | ($2.0m) | — | — | — | — | |
| Repurchase of early exercised stock options | $0 | ($968k) | $0 | — | — | — | — | |
| Proceeds from merger and PIPE transactions, net of transaction costs | $0 | $572.7m | $0 | — | — | — | — | |
| Operating lease right-of-use assets subject to lease liability | — | — | $0 | $2.4m | $6.1m | $0 | — | |
| Remeasurement of operating lease right-of-use assets due to lease modification | — | — | $0 | ($849k) | $0 | — | — | |
| Noncash reclassification of warrant liabilities to equity upon exercise | $0 | $79.7m | $8k | $20k | $69.4m | $532.4m | — | |
| Bonus settled in restricted stock units | — | $0 | $473k | $3.9m | $11.4m | $7.0m | — | |
| Equity issued for intangible assets | — | — | — | $0 | $0 | $48.1m | — | |
| Equity issued for research and development arrangement | — | — | — | $0 | $0 | $68.7m | — | |
| Net share settled stock option exercises | — | — | $0 | $291k | $1.0m | — | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.